Golimumab rejected by NICE for psoriatic arthritis

Golimumab has not been recommended by NICE for use in treating psoriatic arthritis, under draft guidance issued by the institute.

The drug is licensed for the treatment of active and progressive arthritis in adults unresponsive to other therapy.

NICE has made the recommendation because research indicates that golimumab is not more cost-effective than other available options.

A spokesman said: 'NICE currently recommends adalimumab, etanercept and infliximab for the treatment of psoriatic arthritis in people who have peripheral arthritis. The cost-effectiveness analyses found that golimumab was not the most cost effective of the available options currently recommended by NICE.'

A secondary reason for the guidance was uncertainty about possible harmful side-effects of taking the drug, as a long-term follow up on adverse outcomes is ongoing.

The spokesman added: 'Based on the available evidence, golimumab was expected to be more costly than estimated in the economic model and less cost effective than etanercept, and so could not be considered a good use of NHS resources.'

The draft guidance is currently open to consultation.

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register

Already registered?

Sign in

Follow Us:

Just published

COVID-19 vaccine stocks must not be diverted to large sites ahead of local GPs, warns BMA

COVID-19 vaccine stocks must not be diverted to large sites ahead of local GPs, warns BMA

The government must ‘ramp up’ COVID vaccine supplies to general practice and avoid...

UK COVID-19 vaccination programme tracker

UK COVID-19 vaccination programme tracker

GPs across the UK are playing a leading role in the largest-ever NHS vaccination...

GP-led sites behind almost three quarters of COVID-19 jabs in England

GP-led sites behind almost three quarters of COVID-19 jabs in England

GP-led vaccination sites have delivered nearly three quarters of COVID-19 vaccine...

GPs should ignore calls to throw away usable COVID-19 vaccine, says RCGP

GPs should ignore calls to throw away usable COVID-19 vaccine, says RCGP

Suggestions that vaccination sites should throw away usable doses of COVID-19 vaccine...

GPs urged to use influence to dispel COVID-19 vaccine myths and boost BAME uptake

GPs urged to use influence to dispel COVID-19 vaccine myths and boost BAME uptake

GPs have been encouraged to use their ‘huge influence’ to bust misinformation around...

Six in 10 over-80s vaccinated against COVID-19 as figures expose regional variation

Six in 10 over-80s vaccinated against COVID-19 as figures expose regional variation

Six in 10 people aged over 80 in England received a first dose of COVID-19 vaccine...